Deep Vein Thrombosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Deep Vein Thrombosis stocks.

Deep Vein Thrombosis Stocks Recent News

Date Stock Title
Jul 3 SNY Bain, Cinven Weighing Joint Bid for $20 Billion Sanofi Unit
Jul 3 SNY Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Jul 3 SNY Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Jul 3 SNY Sanofi, Regeneron win EU label expansion for Dupixent in COPD
Jul 3 SNY EMA approves Sanofi’s Dupixent for COPD treatment in adults
Jul 3 SNY Update: Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 3 SNY Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Jul 2 SNY Market Chatter: Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits
Jul 1 SNY Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Jul 1 SNY Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
Jul 1 AMPH Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 1 SNY Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Jul 1 SNY Sanofi reports findings from Phase II relapsing MS treatment trial
Jul 1 SNY Sanofi eyes German insulin investment of up to $1.6 billion, source says
Jun 29 SNY Where Will Novavax Be in 1 Year?
Jun 28 AMPH Insider Sale: CFO, EVP & Treasurer William Peters Sells Shares of Amphastar Pharmaceuticals ...
Jun 28 SNY PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
Jun 28 SNY 3 Top Euronext Paris Dividend Stocks With Yields From 4% To 5.1%
Jun 27 SNY Vigil Neuroscience jumps 34% as Sanofi invests $40M
Jun 27 SNY Formation Bio secures $372m funds for AI-driven drug platform
Deep Vein Thrombosis

Deep vein thrombosis (DVT), is the formation of a blood clot in a deep vein, most commonly the legs. Symptoms may include pain, swelling, redness, or warmth of the affected area. About half of cases have no symptoms. Complications may include pulmonary embolism, as a result of detachment of a clot which travels to the lungs, and post-thrombotic syndrome.Risk factors include recent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, and certain genetic conditions. Genetic factors include deficiencies of antithrombin, protein C, and protein S, and factor V Leiden mutation. The underlying mechanism typically involves some combination of decreased blood flow rate, increased tendency to clot, and injury to the blood vessel wall.Individuals suspected of having DVT may be assessed using a clinical prediction rule such as the Wells score. A D-dimer test may also be used to assist with excluding the diagnosis or to signal a need for further testing. Diagnosis is most commonly confirmed by ultrasound of the suspected veins. Together, DVT and pulmonary embolism are known as venous thromboembolism (VTE).Anticoagulation (blood thinners) is the standard treatment. Typical medications include low-molecular-weight heparin, warfarin, or a direct oral anticoagulant. Wearing graduated compression stockings may reduce the risk of post-thrombotic syndrome. Prevention may include early and frequent walking, calf exercises, aspirin, anticoagulants, graduated compression stockings, or intermittent pneumatic compression. The rate of DVTs increases from childhood to old age; in adulthood, about one in 1000 adults are affected per year. About 5% of people are affected by a VTE at some point in time.

Browse All Tags